IPIX legitimized with their deal with Alfasigma.

IPIX legitimized with their deal with Alfasigma.
http://www.ipharminc.com/press-release/2019/7...is?rq=alfa


BDD Pharma just finished a short PI for brilacidin IBD oral dosage.
http://www.ipharminc.com/press-release/2020/1...litis-drug


Locust walk TARGETING a deal for Brilacidin for Oral Mucosa.

Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

GlobeNewswireJanuary 29, 2020

WAKEFIELD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (IPIX) (“the Company”), a clinical stage biopharmaceutical company, has further engaged Locust Walk, a leading global life sciences transaction firm serving as its strategic advisor, to lead the Company’s out-licensing negotiations for rights to oral rinse Brilacidin for the treatment of Oral Mucositis (OM).


The Company had previously engaged Locust Walk to assess the value of its clinical assets, which included recently an in-depth assessment of the commercial opportunity of oral rinse Brilacidin-OM—a Phase 3-ready, FDA Fast Track-designated clinical asset in late-stage development targeting a substantial untapped market in supportive cancer care.

This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.


https://finance.yahoo.com/news/innovation-pha...10697.html



•Objective to further unlock market potential of pipeline and determine the appropriate path forward to enhance shareholder value
•Locust Walk is a global life sciences transaction firm with exceptional strategic insights rooted in their deal experience

BEVERLY, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company has engaged Locust Walk, a leading global life sciences transaction firm. Locust Walk will seek to assist the Company in maximizing the value of its assets.

“It is an exciting time at Innovation,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Our pipeline is innovative, mature, and diversified, targeting therapeutic areas encompassing significant market opportunities—namely, in Inflammatory Bowel Disease, Dermatology, Cancer, and Infectious Disease. With our first global licensing agreement executed in July with Italy’s Alfasigma in Ulcerative Proctitis/Ulcerative Proctosigmoiditis, we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”

“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”

https://www.globenewswire.com/news-release/20...-Firm.html





We have no money.

1 CEO.


And KILLER potential.

Possibly Leo snags a new Chief Medical Officer. Maybe that individual helps change the landscape as well.

Yep. Do your DD on this little puppy.